ForSight Robotics Secures $125M to Transform Cataract Surgery with AI-Powered Robots

By futureTEKnow | Editorial Team

The world of eye surgery is on the verge of a major shift. ForSight Robotics, an Israeli startup, just closed a massive $125 million Series B round to accelerate development of its Oryom robotic platform—technology designed to automate and enhance cataract surgery and other ophthalmic procedures.

Why Robotic Cataract Surgery Matters

Cataract surgery is one of the most common medical procedures globally, with over 4 million operations performed annually in the U.S. alone. Yet, there’s a glaring shortage of skilled surgeons to meet this demand, and the gap is expected to widen as the population ages. ForSight’s Oryom platform aims to address this challenge by delivering robotic precision, consistency, and accessibility—potentially making high-quality eye care available to millions who might otherwise go untreated.

What Makes Oryom Different?

Oryom is billed as the world’s first robotic surgery system built specifically for cataracts and other eye diseases. It leverages:

  • AI algorithms for real-time decision-making.

  • Advanced computer vision to navigate the intricate anatomy of the eye.

  • Miniaturized robotics for dexterity and maneuverability, allowing access to any point within the eye, including complex angles and both anterior and posterior segments.

This technology is engineered for precise, repeatable procedures—a crucial advantage in ophthalmology, where even minor errors can have lasting consequences.

Backed by Industry Veterans

The funding round was led by Eclipse Ventures, with participation from the Adani Group, Reiya Ventures, and Fred Moll—often called the “father of surgical robotics” and a cofounder of Intuitive Surgical, the company behind the da Vinci robot. ForSight’s latest raise brings its total funding to $195 million and values the company at around $500 million, up sharply from its previous valuation in 2022.

What’s Next?

ForSight is preparing to launch its first-in-human clinical trials this year, after extensive testing on animal models. The company is also engaging with the FDA, with initial focus on the U.S. market. If successful, Oryom could set a new standard for robotic eye surgery, opening the door to future applications in glaucoma and retinal procedures.

The Bigger Picture

Robotic surgery is already reshaping fields like general surgery, and the NHS in England projects that by 2035, half a million robotic operations will be performed each year—up from just 70,000 in 2023 and 2024. ForSight’s founders see ophthalmology as the next frontier, with the potential for robotics to deliver safer, more consistent outcomes and to help close the global care gap.

As Dr. Joseph Nathan, cofounder and chief medical officer, puts it:

“We see ophthalmology as the next frontier in the robotics revolution—much like general surgery was before the rise of Intuitive Surgical. With a comparable market size and an urgent global need, our opportunity ahead is immense.”

Key Takeaway:

ForSight Robotics is betting that the future of cataract surgery—and perhaps all eye surgery—will be robotic, AI-driven, and far more accessible than ever before. If Oryom delivers on its promise, the impact could be transformative for millions facing vision loss worldwide.

futureTEKnow covers technology, startups, and business news, highlighting trends and updates across AI, Immersive Tech, Space, and robotics.

futureTEKnow

Editorial Team

Founded in 2018, futureTEKnow is a global database dedicated to capturing the world’s most innovative companies utilizing emerging technologies across five key sectors: Artificial Intelligence (AI), immersive technologies (MR, AR, VR), blockchain, robotics, and the space industry. Initially launched as a social media platform to share technology news, futureTEKnow quickly evolved into a comprehensive resource hub, spotlighting the latest advancements and groundbreaking startups shaping the future of tech.

Trending Companies

Latest Articles